Geriatrics addresses the health needs of older adults, focusing on frailty, dementia, falls, and chronic disease management.
Send us all your questions or requests, and our expert team will assist you.
The landscape of treatment for macular degeneration is currently bifurcated into established protocols for the wet form and emerging, essentially investigative strategies for the dry form. The standard of care has shifted dramatically over the past two decades, moving from laser destruction of abnormal vessels to the era of molecular inhibition with anti-VEGF therapy. Now, the field is pivoting again, this time toward the regenerative frontier. The ultimate goal of modern care is not merely the suppression of pathology but the restoration of physiology. This involves a multi-pronged approach: halting the growth of destructive vessels, modulating the immune system to prevent atrophy, and potentially replacing the cellular architecture that has been lost.
Care management is chronic and intensive, requiring frequent monitoring and interventions. It demands a high level of patient compliance and a robust support system. The treatment paradigm is also increasingly personalized, with research moving toward determining the optimal injection intervals and identifying the specific patient profiles best suited for novel cellular therapies.
For neovascular (wet) macular degeneration, the gold standard treatment involves the intravitreal injection of agents that inhibit Vascular Endothelial Growth Factor (VEGF). VEGF is the protein signal that triggers the growth of abnormal, leaky blood vessels.
Until recently, there were no FDA-approved treatments for the dry form of AMD, specifically Geographic Atrophy. Management relied on nutritional supplementation (AREDS2 formula) to slow progression. However, the landscape is changing with the approval of complement inhibitors.
Medical therapy focuses on halting disease progression and, when possible, restoring vision. For dry AMD, the AREDS2 (Age‑Related Eye Disease Study 2) formulation a combination of vitamins C, E, lutein, zeaxanthin, zinc, and copper has demonstrated a 25 % reduction in progression to advanced stages.
Wet AMD treatment centers on inhibiting vascular endothelial growth factor (VEGF), the protein driving abnormal vessel growth. The most widely used agents include:
Injections are administered intravitreally under sterile conditions, usually every 4–8 weeks. Recent advances such as the Port Delivery System (PDS) provide a sustained‑release platform, reducing visit frequency.
Adjunctive pharmacologic strategies, such as oral complement inhibitors (e.g., pegcetacoplan) for geographic atrophy, are emerging and may become part of the standard treatment and care repertoire pending regulatory approval.
When medical therapy alone is insufficient, surgical interventions can preserve or improve central vision. The primary surgical modalities include:
In addition, Liv Hospital participates in clinical trials exploring gene therapy (e.g., AAV‑mediated delivery of VEGF inhibitors) and stem‑cell‑derived RPE implantation. These cutting‑edge treatments aim to address the underlying pathology rather than merely controlling symptoms.
Selection criteria for surgery include lesion size, visual acuity, and patient health status. A multidisciplinary board reviews each case to ensure that the chosen intervention aligns with the overall care plan and patient preferences.
Medical and surgical options are most effective when complemented by lifestyle modifications that support retinal health. Key recommendations include:
Liv Hospital’s vision‑rehabilitation team provides individualized training with assistive devices, orientation‑and‑mobility counseling, and psychological support to address the emotional impact of vision loss.
International patients benefit from Liv Hospital’s 360‑degree support system, which integrates clinical excellence with logistical assistance. Our dedicated International Patient Services (IPS) team handles:
All clinical interactions adhere to JCI standards, ensuring safety, privacy, and continuity of care. By centralizing administrative tasks, patients can focus on their treatment and care journey without the stress of navigating a foreign health system.
Liv Hospital combines JCI accreditation, a multidisciplinary geriatric ophthalmology team, and a proven track record in managing complex macular degeneration cases. International patients receive personalized medical plans, state‑of‑the‑art facilities, and a seamless support network that covers everything from travel logistics to post‑procedure rehabilitation.
Ready to discuss your personalized macular degeneration plan? Contact our International Patient Services team today to schedule a virtual consultation and take the first step toward preserving your vision.
Send us all your questions or requests, and our expert team will assist you.
Age‑related macular degeneration (AMD) manifests mainly as dry and wet forms. Dry AMD is characterized by gradual thinning of the macula and the buildup of drusen, leading to slow vision loss. Wet AMD, though less common, involves choroidal neovascularization that leaks fluid or blood, causing sudden and severe vision decline. Recognizing the type is essential because treatment strategies differ: dry AMD focuses on nutritional supplementation and monitoring, while wet AMD requires anti‑VEGF injections or other interventions to halt neovascular growth.
The AREDS2 supplement is a specific formulation of vitamins and minerals (Vitamin C, Vitamin E, Zinc, Copper, Lutein, and Zeaxanthin) proven by clinical trials to reduce the risk of progression in people with intermediate dry macular degeneration or early AMD in one eye and advanced in the other. It is not a cure and does not restore lost vision, but it slows the worsening of the disease. It is generally not recommended for those with no AMD or very early-stage AMD.
Currently, stem cell therapy is not a guaranteed “cure” available in general practice, but it is a highly promising investigational treatment. Clinical trials are testing whether transplanting healthy retinal pigment epithelium cells can replace those lost to the disease. The goal is to halt the progression of vision loss and restore some visual function. Results have been encouraging regarding safety and graft survival, but widespread clinical availability depends on further successful trial outcomes.
Surgical interventions are considered for cases where anti‑VEGF therapy does not achieve desired outcomes or when specific lesions are present. Photodynamic therapy (PDT) uses a light‑activated drug to close abnormal vessels. Sub‑retinal surgery can remove scar tissue and fluid, improving retinal architecture. Experimental approaches such as retinal pigment epithelium (RPE) transplantation and gene therapy trials aim to address the underlying disease mechanisms. Selection depends on lesion size, visual acuity, and overall patient health, evaluated by a multidisciplinary board.
Lifestyle modifications complement medical treatment by targeting risk factors. A diet rich in leafy greens, oily fish, and antioxidant‑dense fruits supplies nutrients that support retinal health. Smoking cessation is critical, as smokers have double the risk of AMD progression. Maintaining optimal blood pressure and lipid levels through exercise and medication reduces vascular stress. Protective eyewear limits UV damage, and low‑vision rehabilitation programs help patients maximize remaining vision and maintain independence.
Your Comparison List (you must select at least 2 packages)
